ANDAINTRAVENOUSINJECTABLE
Approved
May 2017
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ESOMEPRAZOLE SODIUM (esomeprazole sodium) by Fosun Pharma is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the h/katpase enzyme system at the secretory surface of the gastric parietal cell. First approved in 2017.
Drug data last refreshed 19h ago
$0.0BPart D
Mechanism of Action
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H/KATPase enzyme system at the secretory surface of the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Worked on ESOMEPRAZOLE SODIUM at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.